Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA appoints biosimilar head

Simon Sturge joins from Boehringer Ingelheim
Simon Sturge, Merck KGaA

Simon Sturge is to leave his role at Boehringer Ingelheim to join fellow German healthcare company Merck KGaA as head of its new biosimilars unit.

From March 1, Sturge will run the company's biosimilars division, which was set up in 2012 to develop copies of biological treatments with a focus on oncology and inflammatory disorders. 

Based in Canton de Vaud, Switzerland, the unit will include both in-house and partnership-based development to create biosimilars, which are seen as a major growth area over the next few years as patents for biological medicines expire.

Sturge is currently head of biopharmaceuticals at Boehringer, where his responsibilities include biosimilars.

His prior experience in pharma includes several CEO positions, such as Vernalis, Lonza Biologics and Celltech Biologics.

With his appointment, Sturge succeeds Thierry Hulot, who created Merck KGaA's biosimilars unit but later took over responsibility for global manufacturing and supply for its pharma unit Merck Serono.

21st February 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics